Failed clinical trials don’t always spell doom for a new drug. Here’s why
This article was adapted from STAT’s latest report, “Failed trial, successful drug: how a negative readout can still lead to FDA approval.”
When a clinical trial readout for what seemed a promising drug comes back negative, investors often contemplate jumping ship and companies wonder if continuing to pursue regulators’ approval is worth the trouble.
Read Original Article: Failed clinical trials don’t always spell doom for a new drug. Here’s why »
